EP2882433B1 - Compositions antimicrobiennes comprenant des nitrates de glycéryle - Google Patents

Compositions antimicrobiennes comprenant des nitrates de glycéryle Download PDF

Info

Publication number
EP2882433B1
EP2882433B1 EP13827577.1A EP13827577A EP2882433B1 EP 2882433 B1 EP2882433 B1 EP 2882433B1 EP 13827577 A EP13827577 A EP 13827577A EP 2882433 B1 EP2882433 B1 EP 2882433B1
Authority
EP
European Patent Office
Prior art keywords
solution
acid
gtn
glyceryl
citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13827577.1A
Other languages
German (de)
English (en)
Other versions
EP2882433A1 (fr
EP2882433A4 (fr
Inventor
Issam Raad
Joel Rosenblatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of EP2882433A1 publication Critical patent/EP2882433A1/fr
Publication of EP2882433A4 publication Critical patent/EP2882433A4/fr
Application granted granted Critical
Publication of EP2882433B1 publication Critical patent/EP2882433B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/02—Acyclic compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds containing nitrogen-to-oxygen bonds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds containing nitrogen-to-oxygen bonds
    • A01N33/18—Nitro compounds
    • A01N33/20—Nitro compounds containing oxygen or sulfur attached to the carbon skeleton containing the nitro group
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/2003—Alcohols; Phenols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/2003—Alcohols; Phenols
    • C11D3/2065—Polyhydric alcohols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/2075—Carboxylic acids-salts thereof
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/39—Organic or inorganic per-compounds
    • C11D3/3947—Liquid compositions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C11D7/261—Alcohols; Phenols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C11D7/265—Carboxylic acids or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D2111/00—Cleaning compositions characterised by the objects to be cleaned; Cleaning compositions characterised by non-standard cleaning or washing processes
    • C11D2111/10—Objects to be cleaned
    • C11D2111/14—Hard surfaces
    • C11D2111/20—Industrial or commercial equipment, e.g. reactors, tubes or engines

Definitions

  • the present invention relates generally to the field of molecular biology and medicine. More particularly, it concerns antimicrobial compositions comprising a glyceryl nitrate.
  • compositions for biofilm eradication where contact with humans or animals can occur generally require high alcohol concentrations, antibiotics and/or relatively toxic concentrations of antiseptic agents.
  • Antibiotics are often expensive and their prophylactic use is problematic due to the potential for inducing antimicrobial resistance.
  • Vascular catheters are currently hydraulically locked with saline or heparin solutions between infusions or blood sampling through lumens.
  • the hydraulically locked lumens are generally capped off between uses.
  • Lumens can become contaminated with bacteria or fungi through introduction of contaminated infusates, by environmental exposure when uncapped, or through manual contact with luers and/or caps.
  • disinfection and salvage of the catheter with an antimicrobial lock can be employed.
  • Antibiotic lock solutions are frequently used but have the disadvantages of being expensive and risking the development of antibiotic-resistant organisms. Infections from antibiotic resistant organisms typically have higher treatment costs and mortalities. High concentration ethanol solutions have also been attempted.
  • Biofilm phenotypes are important in recalcitrant device-associated and nosocomial infections and are much more difficult to eradicate than microbes in the dilute planktonic state.
  • Biofilm formation is often an important part of generating an infection by a bacterial or fungal organism.
  • biofilm formation can cause odor, discoloration, degradation and other significant problems by fouling pipes and other industrial equipment.
  • One medical application of particular interest is disinfection of the lumenal surfaces of vascular catheters. Intralumenal infections are a significant problem for long term catheterized patients who require vascular access for infusion of medications or nutrition.
  • the lumens of the catheters are typically locked with saline or heparin-saline solutions to prevent blood from clotting and occluding the lumens.
  • catheter lumens can become colonized by pathogenic organisms and can become a source of bacteremias or candidemias.
  • Lumenal sourced colonization is the most common cause of late-onset catheter-associated blood stream infections.
  • new antimicrobial compositions that may be used to kill microorganisms present in biofilms.
  • an antimicrobial solution comprising a glyceryl nitrate such as, e . g ., glyceryl trinitrate (GTN, nitroglycerin), in combination with a chelator, a peroxide, a fatty acid, and/or an alcohol are provided and may be used, e . g ., to effectively kill microorganisms in biofilms.
  • GTN glyceryl trinitrate
  • the present invention is based, in part, on the discovery that GTN in combination with a chelator and/or an alcohol may be used to synergistically kill microorganisms present in biofilms such as bacteria or fungi.
  • solutions of the present invention may be used as antimicrobial solutions on medical equipment (e . g ., used as a locking solution in a catheter), for cleaning or flushing oil or gas pipelines, on a food preparation surface, for wound treatment, on periodontal or dental devices or during an oral surgery or dental procedure, or in skin cleaning or antisepsis.
  • An aspect of the present invention relates to an antimicrobial solution comprising a glyceryl nitrate and: an alcohol at a level of greater than about 10% (v/v), a peroxide, a fatty acid, and/or a chelator.
  • the solution may be a liquid, a suspension, or an emulsion in a fluid medium.
  • the solution may comprise the glyceryl nitrate and the chelator.
  • the solution may comprise the glyceryl nitrate, the peroxide, and the chelator.
  • the peroxide may be at a level of about 0.01-10%, more preferably about 0.1-3%, even more preferably about 0.1-2%.
  • the solution comprises the glyceryl nitrate, the fatty acid, and the chelator.
  • the fatty acid may be at a level of about 0.001-10%, more preferably about 0.01-5%, more preferably about 0.05-3%.
  • the solution comprises the glyceryl nitrate and the peroxide.
  • the peroxide may be hydrogen peroxide, benzoyl peroxide, or barium peroxide.
  • the peroxide is an inorganic peroxide such as barium peroxide, calcium peroxide, magnesium peroxide, or strontium peroxide.
  • the peroxide is hydrogen peroxide.
  • the solution may comprise about 0.1-3% hydrogen peroxide.
  • the solution may further comprise the chelator.
  • the solution comprises GTN, the fatty acid, and the chelator.
  • the fatty acid may be a C 6-12 alkanoic acid or a C 6-10 alkanoic acid.
  • the fatty acid is hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid, caprylic acid (octanoic acid), caproic acid, or lauric acid.
  • the fatty acid is caprylic acid (octanoic acid).
  • the solution may comprise about 0.01-5% caprylic acid.
  • the solution may further comprise a surfactant, wetting agent, emollient, moisturizer, scent, or a flavor agent.
  • one or more polymer(s) may be added to the antimicrobial solution to thicken the solution or make the solution more viscous.
  • Antimicrobial solutions containing the polymers as thickeners or to increase the viscosity may be useful, e . g ., in or as a coating.
  • the coating may be comprised on or applied to a medical device, or the may coating be applied to a subject topically or parenterally, e . g ., to reduce the growth of or kill bacteria and fungi.
  • the solution may comprise the glyceryl nitrate and the alcohol.
  • the solution comprises the glyceryl nitrate, the alcohol, and the chelator.
  • the glyceryl nitrate may be glyceryl trinitrate (GTN).
  • GTN glyceryl trinitrate
  • the glyceryl trinitrate may have a concentration of from about 0.05 to about 1500 micrograms/ml, from about 1 to about 1000 micrograms/ml, or from about 10 to about 500 micrograms/ml.
  • the glyceryl nitrate may be glyceryl dinitrate or glyceryl mononitrate.
  • the chelator may be citrate, a tetra acetic acid, a thiosulfate, N-acetyl cysteine, disulfiram, a hydroxy acid, a hydroxamic acid, ethylene diaminedisuccinate (EDDS), Tetrakis hydroxymethyl phosphonium sulfate (THPF), or MesNA.
  • the chelator may be citrate.
  • the chelator may be ethylene diaminedisuccinate (EDDS) or Tetrakis hydroxymethyl phosphonium sulfate (THPF).
  • the chelator is a hydroxy acid, such as an ⁇ -hydroxy acid.
  • the hydroxy acid may be lactic acid, gluconic acid, glycolic acid, galacturonic acid, salicylic acid, or glucaronic acid.
  • the chelator is a hydroxamic acid.
  • the hydroxamic acid may be hydroxamic acid, benzohydroxamic acid, salicylhydroxamic acid, or suberoylanilide hydroxamic acid (SAHA).
  • SAHA suberoylanilide hydroxamic acid
  • the citrate may comprise about 0.1-10%, about 1-10%, about 3.5-7%, or about 4% (v/v) of the solution.
  • the chelator may be MesNA.
  • the MesNA may comprise about 1-10%, or about 5% (v/v) of the solution.
  • the chelator may be disulfiram.
  • the disulfiram may have a concentration of about 0.05 - 5 mg/ml or about 0.1 - 0.5 mg/ml.
  • the alcohol may be ethanol, methanol, isopropanol, butyl alcohol, propylene glycol, benzyl alcohol, chlorobutanol or phenylethyl alcohol.
  • the alcohol may comprise from greater than about 10% to about 80% (v/v), from greater than 10 to about 40%, from about 15 - 30%, or about 20% of the solution.
  • the solution may be further defined as a pharmaceutically acceptable composition or a pharmaceutically acceptable excipient.
  • the solution comprises from greater than 10% to about about 60% ethanol, about 1-20% citrate, and about 10-500 microgram/ml glyceryl trinitrate. In some embodiments, the solution comprises from about 15% to about 30% ethanol, about 2.5-10% citrate, and about 50-250 microgram/ml glyceryl trinitrate.
  • Another aspect of the present invention relates to a non-therapeutic method for reducing microbial organisms from a surface comprising contacting the surface with an antimicrobial solution of the present invention for an amount of time sufficient to reduce microbial organisms on the surface.
  • the microbial organisms may be present in a biofilm on the surface.
  • the surface may be comprised on a catheter, a medical device, a water pipeline, a fluid pipeline, an oil or gas pipeline, an ice machine pipe, or a beverage dispensing pipe. In some embodiments, the surface is comprised on the interior of a vascular catheter.
  • the antimicrobial solution is used as a locking solution or a flush solution for a medical device such as, e . g ., a catheter, or the antimicrobial solution may be applied to a subject topically ( e . g ., to disinfect a portion of the skin of a subject or to clean or disinfect a wound on a subject).
  • a solution comprising a glyceryl nitrate (e.g., GTN), a fatty acid (e.g., C 6-12 alkanoic acid, a C 6-10 alkanoic acid, capyrilic acid), and a chelator may be used as a flush solution.
  • the flush solution may, e .
  • the flush solution may be applied to, used to irrigate or clean, or used at a lavage for a wound on s subject, such as a human subject.
  • a solution comprising a glyceryl nitrate (e.g., GTN), an alcohol (e . g ., ethanol), and a chelator may be used as a locking solution.
  • GTN glyceryl nitrate
  • alcohol e.g ., ethanol
  • a chelator may be used as a locking solution.
  • a solution comprising GTN, 20% ethanol, and chelator was shown to exhibit a 1 year shelf stability.
  • kits comprising an antimicrobial solution of the present invention in a suitable container means.
  • the kit may further comprise instructions for use.
  • the suitable container means may be a vial, syringe or dispenser.
  • the solution may be comprised in or on a swab or wipe.
  • Another aspect of the present invention relates to an antimicrobial solution for use in a method of treating a wound in a subject comprising contacting or administering an antimicrobial solution of the present invention to at least a portion of the wound.
  • a therapeutically effective amount of the antimicrobial solution is applied to the wound.
  • the subject may be a human.
  • the solution may be topically administered to the subject.
  • the solution is administered as a lavage.
  • the method may further comprise irrigating the wound with the solution.
  • the solution may be applied to a wound bed, an epithelial tissue, an endothelial tissue, or an organ surface.
  • the kit comprises an antimicrobial solution in a container that is designed to allow for the solution to be dispensed as a locking solution.
  • the solution may be comprised in a vial or syringe and added or dispensed onto or into a medical device such as, e . g ., a catheter.
  • the kit may contain instructions for use during a medical or cleaning procedure.
  • the kit may be packaged with one or more syringes, swabs or wipes for application.
  • the solution may be comprised in a syringe, vial, tube, cream, ointment, wipe or film.
  • the kit comprises a single solution comprising a glyceryl nitrate and a) an alcohol and/or a chelator.
  • the glyceryl nitrate, alcohol, peroxide, fatty acid, and/or chelator may be contained in separate containers in a kit and mixed ( e . g ., mixed, sonicated, etc .) prior to use. For example, several possibilities are shown below.
  • First container means Second container means Third container means (glyeryl nitrate + alcohol) chelator n/a (glyceryl nitrate + chelator) alcohol or peroxide or fatty acid n/a glyceryl nitrate (chelator + alcohol) n/a glyceryl nitrate alcohol or peroxide or fatty acid chelator glyceryl nitrate (chelator + peroxide) n/a glyceryl nitrate (chelator + fatty acid) n/a
  • the duration of contact needed for disinfecting surfaces by fluid contact can vary by organism and/or by how well established a biofilm is being treated. As shown in the below examples, the inventors have found that biofilms can be eradicated within 2 hours by contact with compositions of low enough toxicity that they are suitable for use in intravascular devices.
  • a solution of the presente invention may be sprayed, nebulized, or inhaled by a subject into a lung, sinus, or respiratory tissue to treat or clean a wound or tissue, or reduce the growth of bacteria or fungi on the tissue.
  • a solution of the present invention may be administered topically to a subject, such as a human patient, to treat or prevent a sexually transmitted disease (STD).
  • STD sexually transmitted disease
  • an antimicrobial composition of the present invention may be formulated into a gel, cream, or film, and the composition may include one or more coloring, aromatic, lubricious, moisturizing, pain relief and/or anti-inflammatory additive.
  • Implanted medical device surfaces to which these compositions can be applied include, but are not limited to, catheters, cords, tubes, drains, shunts, stents, sutures, clips, staples, dressings, meshes, casings, etc.
  • Environmentally exposed surfaces of plants, devices, buildings or machines can be treated with these compositions including surfaces in showers, locker-rooms, bathrooms and medical facilities.
  • Surfaces of personal care and/or protection articles such as gloves, masks, respirators, patches, foot covers, shoe liners, flip flops, ear plugs, nose plugs etc. may be substantially disinfected with these compositions.
  • the antimicrobial compositions of the present invention may be contacted with a surface for a variety of periods of time to kill microorganisms or reduce the growth of microorganisms.
  • the contacting may be performed for at least 1, 2, 3, 4, 5 hours or at least 1, 2, 3, 4, 5 or more days, or 1, 2, 3, 4, 5 or more weeks, etc.
  • the contacting may be performed for less than 5, 4, 3, 2, or 1 hours, or less than 45, 30, or 15 minutes.
  • the present invention provides, in various aspects, compositions and methods for inhibiting microbial growth or biofilm formation on surfaces.
  • a glyceryl nitrate can synergize with an alcohol or a chelator to reduce biofilm formation and/or kill microbes present in biofilms.
  • Antimicrobial solutions or compositions provided herein may be used on surfaces in environments and on products used in medical, personal care, food, veterinary, sanitary, industrial and/or communal spaces.
  • the antimicrobial solutions exhibit little or substantially no mammalian toxicity and/or have little or no adverse impact on materials used to make catheters.
  • antimicrobial solutions provided herein can be applied topically or to the skin or other tissue of a subject, such as a mammal or human.
  • GTN glyceryl trinitrate
  • antimicrobial solutions provided herein may provide a safer and less expensive composition for antimicrobial lock therapy.
  • GTN was observed to demonstrate synergy in bacterial killing or biofilm treatment when combined with peroxide, chelator, (alcohol and chelator), or (fatty acid and chelator).
  • biofilm destruction may be achieved with a solution of the present invention in less than or equal to about 15 min for gram negative bacteria and less than or equal to about 30 min for gram positive in dilute concentrations.
  • the antimicrobial solutions of the present invention may be used, e . g ., to disinfect a surface of a medical device, or they may be used to clean the skin or a wound of or on a subject, such as a mammalian subject or a human patient.
  • the solution may be administered to the subject, e . g ., as a flush solution for a catheter, or the solution may be used to clean or irrigate a wound or in a lavage to treat a wound.
  • the solution may be used topically on the subject, e . g ., to clean the skin of the subject prior to insertion of a needle into the subject.
  • antimicrobial medical device and “medical device” as used herein, refer to an instrument, apparatus, implement, machine, contrivance, implant, or other similar or related article, including a component part, or accessory, which is subjected to sequential antimicrobial contact as described, and is intended for use in the diagnosis, treatment, and/or prevention of disease or other health-related condition in a subject.
  • the subject can be any vertebrate, such as a mammal or a human.
  • Non-limiting examples of antimicrobial medical devices include vascular catheters, such as peripherally insertable central venous catheters, dialysis catheters, long term tunneled central venous catheters, peripheral venous catheters, single-lumen and multiple-lumen short-term central venous catheters, arterial catheters, pulmonary artery Swan-Ganz catheters, and the like; urinary catheters, other long term urinary devices, tissue bonding urinary devices, renal stents, penile prostheses, vascular grafts, vascular access ports, wound drain tubes, hydrocephalus shunts, ventricular drainage catheters, neurologic and epidural catheters, neurostimulators, peritoneal dialysis catheters, pacemaker capsules, artificial urinary sphincters, small or temporary joint replacements, dilators, heart valves, orthopedic prosthesis, spinal hardware, surgical site repair mesh ( e .
  • urinary catheters other long term urinary devices, tissue bonding urinary devices, renal stents, penile prosthese
  • hernia mesh hernia mesh
  • endotracheal tubes biliary stents
  • gastrointestinal tubes gloves (including latex, non-latex and nitrile), other medical garb, charts, bed rails, condoms, colorectal tract implants, male and female reproductive implants, cosmetic or reconstructive implants ( e . g ., breast, chin, cheek, buttock, nasal), medical device envelopes and pouches, including stethoscope drums, orthopedic implants ( e .
  • joint (knee, hip, elbow, shoulder, ankle), prostheses, external fixation pins, intramedullary rods and nails, spine implants), other medical and indwelling devices that may be subject to microbial infestation and/or activity; and metallic devices, such as cardiac pacemakers, defibrillators, electronic device leads, adaptors, lead extensions, implantable infusion devices, implantable pulse generators, implantable physiological monitoring devices, devices for locating an implantable pulse generator or implantable infusion device under the skin, and devices ( e . g . refill needles and port access cannulae) for refilling an implantable infusion device.
  • metallic devices such as cardiac pacemakers, defibrillators, electronic device leads, adaptors, lead extensions, implantable infusion devices, implantable pulse generators, implantable physiological monitoring devices, devices for locating an implantable pulse generator or implantable infusion device under the skin, and devices ( e . g . refill needles and port access cannulae) for refilling an implantable infusion
  • antimicrobial compositions or solutions of the present invention may be used to substantially disinfect or reduce the growth of a microorganism (e . g ., a bacteria of fungi) on a lumenal surface of a vascular catheter; for example the antimicrobial composition or solution may be used to flush the catheter and/or as a locking solution.
  • a microorganism e . g ., a bacteria of fungi
  • antiseptic agent refers to an agent, such as an antibiotic or an antiseptic, capable of preventing or reducing the growth or reproduction of a microorganism, such as a bacterial or fungal microorganism, or of killing a microorganism.
  • antibiotic refers to a compound or agent that is capable of preventing or reducing the growth or reproduction of a bacterium, or of killing a bacterium or fungal organism. Such agents are generally applied in the treatment of systemic infection in a subject.
  • Non-limiting classes of antibiotics include, e . g ., a tetracycline, minocycline, a rifamycin, neomycins, bacitracin, polymixins, aminoglycosides, carbapenems, cephalosporins, cephazolins, azoles, nitrofurantoins and rifampin.
  • Antimicrobial compositions of the present invention may include one or more antibiotic.
  • antiseptic refers to a compound or agent that is capable of preventing or reducing the growth or reproduction of a microorganism (such as bacteria, fungi, protozoa, and viruses), or of killing a microorganism, but which is generally not applied in the treatment of a systemic infection in a subject, usually because of limitations related to absorption, penetration, or systemic toxicity.
  • a non-limiting class of antiseptics that may be included in an antimicrobial composition of the present invention includes guanidium compounds, such as chlorhexidine.
  • Other examples of antiseptics that may be used include phenoxide antiseptics ( e .
  • clofoctol chloroxylenol, triclosan
  • quaternary ammonium compounds cetyl pyridinium compounds, iodine compounds, hypochlorites, menthols, eucalyptols, thymols, salicylates, chlorxylenols, aldehydes, glutaraldehyde, peptides, peptide mimetics, acids, bases, oxidizers, gardine, gendine, genlenol, genlosan, or genfoctol.
  • Chlorhexidine is an antiseptic cleansing agent that is active against staphylococci and other gram-positive bacteria, as well as against various fungi. Chlorhexidine may be included in an antiseptic solution described herein. Chlorhexidine is soluble in both water and organic solutions including alcohols, ketones, ethers, aldehydes, acetonitrile, acetic acid, methylene chloride and chloroform. When utilized herein, the term chlorhexidine may include salts of chlorhexidine. Other antiseptics that may be used instead of or in combination with chlorhexidine include alexidines, octenidines and polyhexamathylbiguanides.
  • organic solvent refers to a solvent that can be used to dissolve antimicrobial agents, and includes, among others, alcohols (e . g ., methanol, ethanol), ketones (e . g ., acetone, methylethylketone), ethers ( e . g ., tetrahydrofuran), aldehydes ( e . g ., formaldehyde), acetonitrile, acetic acid, methylene chloride and chloroform.
  • alcohols e . g ., methanol, ethanol
  • ketones e . g ., acetone, methylethylketone
  • ethers e . g ., tetrahydrofuran
  • aldehydes e . g ., formaldehyde
  • acetonitrile acetic acid
  • methylene chloride and chloroform e.g ., ethanol
  • penetrating agent refers to an agent, such as an organic compound, that is capable of promoting penetration of an antimicrobial agent, such as a guanidium compound, into the matrix of the medical device.
  • an antimicrobial agent such as a guanidium compound
  • Non-limiting examples of such compounds are esters ( e . g ., ethyl acetate, propyl acetate, butyl acetate, amyl acetate, and combinations thereof), ketones ( e . g ., acetone and methylethylketone), methylene chloride and chloroform.
  • An antimicrobial solution of the present invention may comprise one or more penetrating agent and/or organic solvent.
  • alkalinizing agent refers to organic and inorganic bases, including sodium hydroxide, potassium hydroxide, ammonia in water ( e . g ., 27% ammonium hydroxide), diethylamine and triethylamine.
  • An antimicrobial solution of the present invention may comprise an alkalinizing agent.
  • bacteria and fungal organisms means all genuses and species of bacteria and fungi, including but not limited to all spherical, rod-shaped, and spiral bacteria.
  • bacteria include staphylococci (e . g ., Staphylococcus epidermidis , Staphylococcus aureus ), Enterrococcus faecalis, Pseudomonas aeruginosa , Escherichia coli , among other gram-positive bacteria and gram-negative bacilli.
  • Non-limiting examples of fungal organisms include Candida albicans and Candida krusei.
  • Medical devices that are amenable to treatment according to a method of the present invention generally include non-metallic materials, such as rubber, plastic, polyethylene, polyurethane, silicone, polytetrafluoroethylene (PTFE), polyethylene terephthalate (PET), latex, nitrile, and other polymeric and elastomeric materials, as well as metals, such as titanium, and metal alloys, such as stainless steel and nitinol.
  • non-metallic materials such as rubber, plastic, polyethylene, polyurethane, silicone, polytetrafluoroethylene (PTFE), polyethylene terephthalate (PET), latex, nitrile, and other polymeric and elastomeric materials
  • metals such as titanium, and metal alloys, such as stainless steel and nitinol.
  • washing refers to the application of a liquid to the medical device for the purpose of removing a substance.
  • washing may be further defined as contacting the surface of the medical device with de-ionized water. The contacting may result in removal of antimicrobial agent and solvent not bound to the medical device.
  • Any method known to those of ordinary skill in the art can be applied in washing the medical device. Washing can, for example, include rinsing, dipping, or immersing the device in a wash solution using any method known to those of ordinary skill in the art.
  • an antiseptic solution of the present invention may be heated, e . g ., during application to a medical device.
  • heating refers to an increase in the temperature of a composition due to application of a heat source, when compared to the temperature of the composition in the absence of the heat source. Heating can be by any method known to those of ordinary skill in the art.
  • the present invention is based, in part, on the discovery that glycerol nitrates, such as glyceryl trinitrate (GTN), may be included in an antimicrobial composition in combination with an alcohol and/or a biofilm disrupting agent such as a chelator to kill microbes, e . g ., present in a biofilm.
  • GTN glycerol nitrate
  • a biofilm disrupting agent such as a chelator to kill microbes, e . g ., present in a biofilm.
  • GTN glyceryl trinitrate
  • Glyceryl nitrates include mono-, di-, or trinitrates (e . g ., glyceryl mononitrate, glyceryl dinitrate, or glyeryl trinitrate). Mixtures of glyceryl mononitrate, glyceryl dinitrate, and/or glyeryl trinitrate may be used in various embodiments of the present invention.
  • GTN is also referred to as nitroglycerin, nitroglycerine, trinitroglycerin, trinitroglycerine, 1,2,3-trinitroxypropane, and glyceryl trinitrate
  • glyceryl nitrate such as for example GTN
  • the glycerol nitrate may be present in an antimicrobial composition or solution of the present invention in an amount of about 0.05-2000, 0.1-2000, 0.1-1750, 0.1-1500, 0.1-1250, 0.1-1000, 1-1000, 10-500, 25-500, 25-250, 50-500, 75-150, or about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 micrograms/ml, or any range derivable therein.
  • intermediate concentrations such as, e .
  • the concentration of the glyceryl nitrate may be greater than about 10, 11, 12, 13, 14, 15, 20, or 25 micrograms/ml.
  • the glyceryl nitrate may be in a concentration less than about 2000, 1750, 1500 micrograms/ml.
  • about 50-125 or about 100 micrograms/ml glyceryl nitrate may be included in a locking solution, such as an intravascular antimicrobial catheter locking solution, as these concentrations can be safely used clinically.
  • the glyceryl nitrate is GTN.
  • a glyceryl nitrate is preferably included in an antimicrobial composition or solution in combination with an additional antimicrobial agent, such as an alcohol or a chelating agent.
  • an additional antimicrobial agent such as an alcohol or a chelating agent.
  • about 25-250 micrograms/ml GTN may be included in an antiseptic composition or solution in combination with, e . g ., about 10-70, 15-50, 15-50, 15-30, or about 20%, or any range therein, of an alcohol such as ethanol; these concentrations may be particularly useful in locking solutions or in embodiments where some amount of the antiseptic may be administered or injected into a subject, such as a human patient.
  • an antimicrobial composition may comprise greater than 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20% of an alcohol such as ethanol.
  • an antimicrobial solution may contain about 20% ethanol, about 7% citrate, and about 100 microgram/ml nitroglycerin; these compositions and concentrations may be particularly suitable for safe intravascular antimicrobial catheter lock use.
  • a glyceryl nitrate is present in an antimicrobial solution.
  • solutions i . e ., liquids, comprising a glyceryl nitrate and an additional antimicrobial agent
  • various gels or semi-solid compositions may be used in various embodiments.
  • the compositions can be allowed to dry such that they form protective antimicrobial coatings that become activated on contact with liquids.
  • an antimicrobial solution comprising GTN may be a water-based or an aqueous solution. Nonetheless, it is anticipated that non-aqueous solutions of GTN, e .
  • compositions comprising an organic solvent or an inorganic nonaqueous solvent (i . e ., a solvent other than water) may be used in various aspects of the present invention.
  • the antimicrobial compositions can be applied to ultimately form a coating or be impregnated into articles. In the case of coatings it may be advantageous to include other polymers that bind the glyceryl nitrate compositions on drying.
  • glyceryl nitrate is preferably included in certain preferred embodiments of the present invention, it is anticipated that a nitrate ether or nitroalcohol could be used instead of, or in combination with, a glyceryl nitrate.
  • nitrate ethers which may be included in an antimicrobial composition or solution of the present invention include nitrophenylethers, nitrohalogenatedethers and nitroalkylethers.
  • An antimicrobial solution of the present invention may comprise an alcohol.
  • Alcohols that may be used with the present invention include ethanol, methanol, isopropanol, butyl alcohol, propylene glycol, benzyl alcohol, chlorobutanol, phenylethyl alcohol, and the like.
  • the alcohol may be a polyol such as, e . g ., sugar alcohols, diols ( e . g ., dipropylene glycol), triols ( e . g ., tripropylene glycols), polyalcohols, etc.
  • the alcohol may be a glycerol or a glycol such as, e.g., propylene glycol.
  • the concentration of the alcohol is preferably in the range of 5%-80% (v/v), from about 10% to about 50%, from 15% to 40%, about 20-30%, or about 20%.
  • the alcohol may be present in an antimicrobial solution of the present in at a concentration of, e . g ., include 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% (v/v), or any range derivable therein.
  • the concentration of the alcohol is greater than about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20%.
  • a lower concentration of the alcohol such as, e . g ., from greater than about 10% to about 40%, about 10-30%, or about 20% (v/v) may be used in order to reduce or substantially eliminate toxicity.
  • intermediate concentrations of alcohol such as 11%, 22.5%, 26% and the like are also contemplated.
  • a lower alcohol concentration may have less impact on the physical properties of the plastic the catheter is made from and may reduce risk to the patient whose veins the catheter indwells in.
  • Ethanol can function as a cosolvent with GTN in aqueous solutions, as GTN has low water solubility by itself.
  • An antimicrobial solution comprising GTN may further comprise a biofilm disrupting agent such as a chelator.
  • the chelator is selected from the group consisting of citrates, a tetra acetic acid, a thiosulfate, N-acetyl cysteine, disulfiram and MesNA. Nonetheless, a wide variety of chelator agents are contemplated as useful in preparing the antimicrobial solutions of the invention.
  • any chelator which binds barium, calcium, cerium, cobalt, copper, iron, magnesium, manganese, nickel, strontium, gallium or zinc will be acceptable for use in the present invention.
  • Other biofilm disrupting agents that can be useful in combination with glyceryl nitrates include enzymes, D-amino acids and quorum sensing inhibitors.
  • EDDS or THPS may be preferably included in a solution that will be used to clean a pipeline or remove or disinfect a biofilms from an oil pipeline.
  • the chelator is a hydroxy acid (also called fruit acids) or a hydroxamic acid.
  • the hydroxy acid may comprise, e . g ., one or more of lactic acid, gluconic acid, citric acid, galacturonic acid, salicylic acid, glycolic acid, or glucaronic acid.
  • the hydroxamic acid may be hydroxamic acid, benzohydroxamic acid, salicylhydroxamic acid, or suberoylanilide hydroxamic acid (SAHA). Additional hyroxamic acids that may be used with the present invention or included in an antimicrobial solution of the present invention are described in Muri et al. (2002) and Pal and Saha (2012).
  • the chelator may be present in polymeric form such as polygalacturonic acid, polyglycolic acid, poly lactic acid, polyhydroxamic acids, or copolymers.
  • the chelator may be present in a latent or protected form such as an ester or anhydride, that can be activated by hydrolysis, e.g., via gluconolactone, or lactide glycolide, etc.
  • citrate refers to the conjugate base of citric acid and includes salts of citrate.
  • Citrate in a solution may come from, e . g ., trisodium citrate, also called sodium citrate, or any other citrate salt.
  • concentrations of citrate may be used with the present invention. For example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20% or more or any range derivable therein may be used.
  • a concentration of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% or any range derivable therein e . g ., 1-10, 5-9, 5-7.5% etc .
  • a locking solution such as a catheter locking solution.
  • the solution comprises a fatty acid, or a fatty acid ester or anhydride.
  • a fatty acid e.g., a C 6-12 alkanoic acid or a C 6-10 alkanoic acid, in combination with a glyceryl nitrate ( e .
  • g ., GTN g., GTN
  • a chelator may be used as a lock solution in a medical device such as, e.g., a catheter.
  • the pH of the solution comprising the fatty acid should be below the pK of the fatty acid, such that the fatty acid is protonated.
  • protonation of the fatty acid may be critical or necessary for improved antibacterial activity of the fatty acid.
  • the solution may be substantially or completely neutralized to about pH 7, and at this pH the fatty acid may be neutralized and then metabolized as a nutrient by the subject.
  • the wound may display a somewhat reduced pH as compared to the subject, for example a pH of about 5 may be observed in a wound fluid although the mammalian or human subject has blood at about pH 7 throughout the majority of the subject.
  • a portion of the fatty acids in the solution may be neutralized when applied to a wound, it is anticipated that a significant and/or synergistic antibacterial killing may occur on the wound as a result of the antimicrobial solution.
  • the fatty acid may be a C 6-12 alkanoic acid or more preferably a C 6-10 alkanoic acid.
  • the fatty acid may be hexanoic acid, decanoic acid, dodecanoic acid, caprylic acid (octanoic acid), caproic acid, or lauric acid.
  • the fatty acid is caprylic acid.
  • Biofilm eradication experiments were conducted using the Modified Kuhns Biofilm Eradication Model. Briefly, silicone discs made from medical grade elastomer were placed into a 24 well tissue culture plate and incubated overnight in plasma at 37°C. The plasma was then removed and replaced with 1mL of 5.5x10 5 CFU/mL inoculum of challenge organisms. Methicilin resistant Staphyloccus aureus (MRSA), Pseudomonas aeruginosa (PA) and Candida albicans (CA) were selected as representative virulent gram positive, gram negative and fungal pathogens causing infections. The plates were then incubated for an additional 24hrs at 37°C allowing sufficient time for formation of a mature biofilm.
  • MRSA Methicilin resistant Staphyloccus aureus
  • PA Pseudomonas aeruginosa
  • CA Candida albicans
  • Inoculum was then removed and discs were washed shaking for 30 minutes in 0.9% sterile saline. After washing the discs were placed in 1mL of various disinfecting solutions and incubated at 37°C for 2 hrs. The discs were then removed and placed in 5mL of 0.9% sterile saline containing neutralizer and sonicated to disrupt any remaining biofilm. The resulting solution was then quantitatively cultured by making serial dilutions in 0.9% sterile saline and plating on agar plates, (TSA+5% sheep blood) for all bacterial organisms and on Sabouraud Dextrose Agar plates for yeasts. Complete eradication of the biofilm requires a recovery of no viable colonies following treatment.
  • GTN concentration of GTN can be reduced 10-fold (to 100 microgram/ml) to what otherwise would be needed by itself, in the presence of ethanol and citrate, to fully eradicate mature biofilms within 2 hours. These levels attain those which are safe concentrations for intravenous or topical use. Similar synergy is seen with GTN and single or combinations of other chelators (GTN and citrate against CA and PA, GTN and MesNA against PA, GTN, citrate and Disulfiram against MRSA and PA, and GTN, citrate and MesNA against PA).
  • the ethanol-citrate-GTN composition is particularly useful for vascular catheter antimicrobial lock therapy where it can more safely and economically eliminate the need for antibiotics or high ethanol concentrations required for colonized catheter salvage.
  • FIGS. 1A-B illustrates synergy of GTN and citrate for GTN at 0.5 mg/ml concentration against P . aeruginosa and additionally for GTN at 1 mg/ml concentration against C . albicans.
  • FIGS 5-7 show GTN synergies with citrate at a series of ethanol concentrations. Specifically the series of Figures show how the synergistic GTN concentration can be reduced as ethanol concentration is increased.
  • FIG. 5 shows that at 10% ethanol and 7% citrate, a GTN concentration of 0.2 mg/ml eradicated P.aeruginosa and C. albicans and a GTN concentration of 0.5 mg/ml fully eradicated MRSA.
  • FIG. 6 shows that when the ethanol concentration is increased to 15%, the GTN concentration required to eradicate to eradicate MRSA was reduced to 0.2 mg/ml.
  • FIG. 7 shows that when the ethanol concentration is further increased to 20%, the GTN concentration required to eradicate MRSA is reduced to 0.1 mg/ml.
  • compositions for Inhibiting Biofilms Utilizing Glyceryl Nitrates
  • biohancers, chelators and combinations were studied in combination with GTN against Staphylococcus aureus , Pseudomonas aeruginosa and Candida albicans biofilms.
  • Biofilm eradication studies (similar to experiments 1-7) were run on silicone disks where biofilms were allowed to form for 24 hours. Exposure times to disinfecting solutions was for times ranging from 15 minutes to 2 hours followed by quantitative enumeration of viable colony forming units (CFU) per square cm of disk by sonication and quantitative plating.
  • CFU viable colony forming units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pest Control & Pesticides (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Claims (19)

  1. Solution antimicrobienne comprenant un nitrate de glycéryle en combinaison avec un chélatant et/ou un acide alcanoïque en C6 à C12, dans laquelle, si le chélatant est un citrate, le citrate représente 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ou 20 % ou n'importe quelle plage pouvant en dériver.
  2. Solution selon la revendication 1, laquelle solution comprend de plus un alcool à raison de plus de 10 % (v/v) et/ou un peroxyde.
  3. Solution selon la revendication 1, laquelle solution comprend :
    (a) le nitrate de glycéryle, l'alcool, et le chélatant ;
    (b) le nitrate de glycéryle et l'acide alcanoïque en C6 à C12 ;
    (c) le nitrate de glycéryle, le peroxyde, et le chélatant ; ou
    (d) le nitrate de glycéryle, l'acide alcanoïque en C6 à C12, et le chélatant.
  4. Solution selon la revendication 3, dans laquelle le peroxyde est présent à raison de 0,01 à 10 %, de 0,1 à 3 %, ou de 0,1 à 2 %.
  5. Solution selon la revendication 3, dans lequel l'acide alcanoïque en C6 à C12 est présent à raison de 0,001 à 10 %, de 0,01 à 5 %, ou de 0,05 à 3 %.
  6. Solution selon la revendication 1, laquelle solution comprend du GTN, l'acide alcanoïque en C6 à C12, et le chélatant, en particulier dans laquelle l'acide alcanoïque en C6 à C12 est un acide alcanoïque en C6 à C10, l'acide hexanoïque, l'acide octanoïque, l'acide décanoïque, l'acide dodécanoïque, l'acide caprylique (acide octanoïque), en particulier 0,01 à 5 % d'acide caprylique, d'acide caproïque, ou d'acide laurique.
  7. Solution selon la revendication 1, laquelle solution comprend en outre un tensioactif, un agent mouillant, un émollient, un hydratant, un parfum, ou un agent aromatisant.
  8. Solution selon la revendication 1, dans laquelle le nitrate de glycéryle est le trinitrate de glycéryle (GTN), en particulier dans laquelle le trinitrate de glycéryle a une concentration de 0,05 à 1500 microgrammes/ml, de 1 à 1000 microgrammes/ml, ou de 10 à 500 microgrammes/ml, ou dans laquelle le nitrate de glycéryle est le dinitrate de glycéryle ou le mononitrate de glycéryle.
  9. Solution selon la revendication 1, dans laquelle le chélatant est un citrate, un acide tétraacétique, un thiosulfate, la N-acétylcystéine, le disulfiram, un hydroxyacide, un acide hydroxamique, le disuccinate d'éthylènediamine (EDDS), le sulfate de tétrakishydroxyméthylphosphonium (THPS), ou le MesNA, en particulier dans laquelle l'hydroxyde acide est un α-hydroxyacide, l'acide lactique, l'acide gluconique, l'acide glycolique, l'acide galacturonique, l'acide salicylique, ou l'acide glucaronique.
  10. Solution selon la revendication 9, dans laquelle l'acide hydroxamique est l'acide hydroxamique, l'acide benzhydroxamique, l'acide salicylhydroxamique, ou l'acide subéroylanilide-hydroxamique (SAHA).
  11. Solution selon la revendication 9, dans laquelle le citrate représente 1 à 10 %, 3,5 à 7 % ou 4 % de la solution, ou dans laquelle le MesNA représente 1 à 10 % (v/v) ou 5 % de la solution, ou dans laquelle le disulfiram a une concentration de 0,05 à 5 mg/ml.
  12. Solution selon la revendication 2, dans laquelle l'alcool est l'éthanol, le méthanol, l'isopropanol, l'alcool butylique, le propylèneglycol, l'alcool benzylique, le chlorobutanol ou l'alcool phényléthylique.
  13. Solution selon la revendication 2, dans laquelle l'alcool représente de plus de 10 % à 80 % (v/v) de la solution, ou dans laquelle la concentration de l'alcool est située dans la plage allant de 10 à 40 %, ou de 15 à 30 % (v/v), ou dans laquelle la concentration de l'alcool est de 20 %.
  14. Solution selon la revendication 2, laquelle solution comprend de plus de 10 % à 60 % d'éthanol, de 1 à 20 % de citrate, et de 10 à 500 microgrammes/ml de trinitrate de glycéryle, ou laquelle solution comprend de 15 % à 30 % d'éthanol, de 2,5 à 10 % de citrate, et de 50 à 250 microgrammes/ml de trinitrate de glycéryle.
  15. Solution selon la revendication 2, laquelle solution comprend de 25 à 250 microgrammes/ml de GTN et de 15 à 30 % d'un alcool.
  16. Solution selon la revendication 2, laquelle solution comprend de 10 à 30 % d'éthanol, du GTN à une concentration de 1 à 100 microgrammes/ml, et 1 à 10 % de citrate.
  17. Procédé non thérapeutique pour réduire les organismes microbiens sur une surface, comprenant la mise en contact de la surface avec une solution antimicrobienne de l'une quelconque des revendications 1 à 16 pendant un temps suffisant pour réduire les organismes microbiens sur la surface.
  18. Solution antimicrobienne selon l'une quelconque des revendications 1 à 16, pour une utilisation dans un procédé de traitement d'une plaie chez un sujet ou de la peau d'un sujet ou d'une surface d'un dispositif médical implanté, dans laquelle le procédé comprend l'administration ou la mise en contact de la solution antimicrobienne sur au moins une partie de la plaie ou de la peau ou de la surface du dispositif médical implanté.
  19. Utilisation de la solution antimicrobienne selon la revendication 1 en tant que solution bouchon ou en tant que solution de rinçage pour un cathéter ou un dispositif médical.
EP13827577.1A 2012-08-08 2013-08-08 Compositions antimicrobiennes comprenant des nitrates de glycéryle Active EP2882433B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680964P 2012-08-08 2012-08-08
PCT/US2013/054129 WO2014025994A1 (fr) 2012-08-08 2013-08-08 Compositions antimicrobiennes comprenant des nitrates de glycéryle

Publications (3)

Publication Number Publication Date
EP2882433A1 EP2882433A1 (fr) 2015-06-17
EP2882433A4 EP2882433A4 (fr) 2016-01-06
EP2882433B1 true EP2882433B1 (fr) 2019-03-13

Family

ID=50068568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13827577.1A Active EP2882433B1 (fr) 2012-08-08 2013-08-08 Compositions antimicrobiennes comprenant des nitrates de glycéryle

Country Status (8)

Country Link
US (2) US9457002B2 (fr)
EP (1) EP2882433B1 (fr)
JP (1) JP6175140B2 (fr)
AU (1) AU2013299575B2 (fr)
CA (1) CA2881361C (fr)
DK (1) DK2882433T3 (fr)
ES (1) ES2729968T3 (fr)
WO (1) WO2014025994A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778387B2 (en) 2009-09-02 2014-07-15 Hyprotek, Inc. Antimicrobial medical dressings and protecting wounds and catheter sites
WO2011091322A2 (fr) * 2010-01-22 2011-07-28 Hyprotek, Inc. Agents antimicrobiens et procédés d'utilisation associés
US9192443B2 (en) 2012-02-06 2015-11-24 Hyprotek, Inc. Combined cap applicators
EP2882433B1 (fr) * 2012-08-08 2019-03-13 Board of Regents, The University of Texas System Compositions antimicrobiennes comprenant des nitrates de glycéryle
BR112015027158A8 (pt) * 2013-05-02 2018-08-14 Next Science Llc Composição antimicrobiana de alta osmolaridade contendo um ou mais solventes orgânicos
WO2015077798A1 (fr) * 2013-11-25 2015-05-28 Excelsior Medical Corporation Formulations de solution de blocage de cathéter
EP3190883A1 (fr) 2014-09-09 2017-07-19 Lonza Inc. Composition désinfectante contenant des composés d'ammonium quaternaire
CN107404879B (zh) 2015-03-18 2021-05-07 营养与生物科技美国第二有限公司 冻结稳定型四(羟甲基)鏻硫酸盐制剂
CN108697826A (zh) * 2016-02-12 2018-10-23 医疗部件有限公司 导管封管液及导管封管法
JP6947756B2 (ja) 2016-02-22 2021-10-13 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 抗菌組成物およびその使用
DE102017200310B3 (de) * 2017-01-10 2017-11-02 Axagarius Gmbh & Co. Kg Test zur Bestimmung der Sulfatkonzentration
CN115990296A (zh) 2017-09-22 2023-04-21 贝克顿·迪金森公司 用作导管封管液的4%柠檬酸三钠溶液
WO2019104162A1 (fr) * 2017-11-25 2019-05-31 Ash Access Technology, Inc. Solution de rinçage de cathéter comprenant du citrate de sodium et de l'alcool benzylique
US11612403B2 (en) * 2018-10-03 2023-03-28 Covidien Lp Multi-function surgical transection instrument
WO2021229574A1 (fr) * 2020-05-13 2021-11-18 Corolabs Ltd. Compositions pour inhalation et leurs utilisations pour désinfecter les voies respiratoires supérieures
US20220080020A1 (en) * 2020-08-22 2022-03-17 Luc Montagnier Compositions and methods for reducing the transmissivity of illnesses using an oral delivery system
CN112604176B (zh) * 2021-01-14 2022-01-25 中南大学湘雅医院 一种颌骨缺损个性化修复后适应装置

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039999A1 (fr) * 1980-05-09 1981-11-18 Warner-Lambert Company Ensemble pour infusion de nitroglycerine
JPH0645538B2 (ja) * 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
US5217493A (en) 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5624704A (en) 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6267979B1 (en) 1997-08-26 2001-07-31 Wake Forest University Chelators in combination with biocides: treatment of microbially induced biofilm and corrosion
WO2001043735A1 (fr) * 1999-12-15 2001-06-21 Cellegy Pharmaceuticals, Inc. Onguent a la nitroglycerine pour le traitement de douleurs associees a une maladie anale
WO2002082907A1 (fr) 2001-01-12 2002-10-24 Board Of Regents, The University Of Texas System Nouveaux derives antiseptiques antimicrobiens a large spectre destines a l'impregnation de surfaces
PT1644024T (pt) 2003-06-06 2019-10-24 Univ Texas Soluções antimicrobianas de lavagem por infusão.
EP1706216A4 (fr) 2004-01-20 2009-07-08 Univ Texas Procedes de revetement et d'impregnation de dispositifs medicaux au moyen de compositions antiseptiques
WO2007062306A2 (fr) 2005-11-18 2007-05-31 The Board Of Regents Of The University Of Texas System Procede permettant de revetir des surfaces d'un agent antimicrobien
US20090312279A1 (en) 2005-12-23 2009-12-17 Sterilex Technologies, Llc Antimicrobial compositions
JP2012520745A (ja) 2009-03-20 2012-09-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医療装置に抗菌活性を付与するための方法
US9072296B2 (en) * 2009-03-26 2015-07-07 Organic Medical Ventures, L.L.C. Transdermal venous access locking solutions
EP2882433B1 (fr) * 2012-08-08 2019-03-13 Board of Regents, The University of Texas System Compositions antimicrobiennes comprenant des nitrates de glycéryle

Also Published As

Publication number Publication date
EP2882433A1 (fr) 2015-06-17
US9457002B2 (en) 2016-10-04
US9913820B2 (en) 2018-03-13
ES2729968T3 (es) 2019-11-07
US20150196523A1 (en) 2015-07-16
EP2882433A4 (fr) 2016-01-06
US20160374978A1 (en) 2016-12-29
AU2013299575A1 (en) 2015-02-26
JP6175140B2 (ja) 2017-08-02
CA2881361A1 (fr) 2014-02-13
WO2014025994A1 (fr) 2014-02-13
JP2015525801A (ja) 2015-09-07
DK2882433T3 (da) 2019-05-27
AU2013299575B2 (en) 2017-11-16
CA2881361C (fr) 2022-03-08

Similar Documents

Publication Publication Date Title
US9913820B2 (en) Antimicrobial compositions comprising glyceryl nitrates
US11826332B2 (en) Antimicrobial compositions and uses thereof
US9380780B2 (en) Transdermal venous access locking solutions
US9433209B2 (en) Transdermal venous access locking solutions
US20030065292A1 (en) Ozonated medical devices and methods of using ozone to prevent complications from indwelling medical devices
US20120282351A1 (en) System and Method for The Prevention of Bacterial and Fungal Infections Including Urinary Tract Infections (UTI) Using N-Halogenated Amino Acids
KR20160096678A (ko) 감염을 억제하기 위한 물질 및 방법
JP2009517335A (ja) 次亜ハロゲン酸組成物を用いた尿路感染（ｕｔｉ）を含む細菌・菌類感染の防止及び処理のためのシステム及び方法
JP2012520745A (ja) 医療装置に抗菌活性を付与するための方法
CA2807362C (fr) Solution verrou antimicrobienne a base d&#39;acide chlorhydrique pour catheter et methode d&#39;utilisation associee
AU2011375794B2 (en) Transdermal venous access locking solutions
US9427498B2 (en) Syringe treated with transdermal venous access locking solutions and method of treating the syringe
WO2024030261A1 (fr) Formulations antimicrobiennes et leurs procédés d&#39;utilisation
TWI566790B (zh) 皮膚穿透靜脈接觸鎖定溶液
KR20220033730A (ko) 차아염소산 및 아세트산을 포함하는 항균 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150304

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151207

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/04 20060101ALI20151201BHEP

Ipc: A61P 31/00 20060101ALI20151201BHEP

Ipc: A61K 31/21 20060101AFI20151201BHEP

Ipc: A61K 31/045 20060101ALI20151201BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180412

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20180822

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1106737

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013052407

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190520

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190613

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190614

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1106737

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190713

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2729968

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20191107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013052407

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190713

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20191216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20190831

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20190901

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190808

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190808

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190901

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230810

Year of fee payment: 11

Ref country code: IE

Payment date: 20230809

Year of fee payment: 11

Ref country code: ES

Payment date: 20230908

Year of fee payment: 11

Ref country code: CH

Payment date: 20230902

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240620

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240621

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240612

Year of fee payment: 12